Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessNovo Nordisk’s weight loss drug Wegovy reduces the risk of those with...

Novo Nordisk’s weight loss drug Wegovy reduces the risk of those with heart disease and obesity

Add to Favorite
Added to Favorite
Image: Photo by Los Muertos Crew: Pexels

The complete results of the Novo’s Select trial were concurrently published in the New England Journal of Medicine and presented by researchers on Saturday at the American Heart Association Scientific Sessions.

According to new research presented, Novo Nordisk (NOVOb.CO) indicated that the heart-protective advantages of its highly effective Wegovy obesity therapy are caused by more than just weight loss.

Wegovy has been found to help patients lose an average of 15% of their body weight. Early data from the Danish drugmaker’s Select study, which was disclosed in August, also showed that Wegovy lowered the incidence of heart attack, stroke, or death from heart disease by 20%.

The New England Journal of Medicine concluded in the study: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. Source: (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.)  NEJM.org.

CNBC reported, “The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week.”

Celebrity WEB Update— Premier Jewelry designer and manufacturer fashion house ParisJewelry.com has started manufacturing a new custom line of celebrity jewelry designs with 30% Off and Free Shipping. Replenish Your Body- Refilter Your Health with OrganicGreek.com Vitamin Bottles, Vitamins and Herbs. Become a  WebFans  Creator and Influencer. Check the New Special XMicro Razors for Men & Women, 1 Razor, 7 Blade Refills with German Stainless Steel, Lubricated with Vitamin E for Smooth Shave, Shields Against Irritation, Version X

Subscribe to get Latest News Updates

Latest News

You may like more
more

Interactive Brokers Group, Inc. (NASDAQ:IBKR) Earnings Preview

Interactive Brokers Group, Inc. (NASDAQ:IBKR) is set to release...

Domino’s Beats Q3 Earnings Expectations But Misses on Revenue

Domino's Pizza (NYSE:DPZ) reported third-quarter results that surpassed earnings...

Truist Securities Upgrades Nike to Buy, Citing Positive Long-Term Prospects with New Leadership

Truist Securities analysts upgraded Nike (NYSE:NKE) to Buy from...